CA-NETAPP
9.12.2021 14:02:09 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today revealed findings from its survey assessing the adoption of hybrid cloud strategies and operational focus areas among NetApp’s global enterprise customer base.
The survey of IT decision makers and infrastructure owners around the world found that 77 percent plan to operate their businesses in hybrid cloud environments for the foreseeable future in order to meet growing business demands for faster innovation, while optimizing operations and lowering infrastructure costs.
“Speed is the new scale. IT leaders everywhere are accelerating digital transformation efforts, requiring more agility and flexibility to stay ahead of their competition and deliver immediate business impact,” said Ronen Schwartz, General Manager and Senior Vice President, Cloud Volumes at NetApp. “Enterprises are embracing hybrid cloud models to effectively scale out IT resources to support business-critical applications and workloads – and NetApp is leading the industry in providing hybrid multi-cloud solutions to meet these organizations wherever they are.”
Highlights from NetApp’s 2021 Hybrid Cloud Enterprise Customer Adoption Survey include:
-
The Future is Hybrid Cloud
: More than three-quarters of respondents said their organization plans to operate a hybrid cloud environment for the foreseeable future, while only 17 percent expect their organization to eventually migrate all IT to the cloud. Those surveyed listed the most important business benefits of hybrid cloud adoption to be:
- Faster Innovation - 26 percent
- Increased Responsiveness to Customers - 25 percent
- Increased Collaboration - 22 percent
- Key Operational Drivers for Hybrid Cloud Adoption : Respondents indicated they are looking to improve infrastructure flexibility and scale (27 percent), as hybrid cloud designs help IT teams get access to the on-demand and emerging technologies offered by public cloud while still leveraging legacy systems running reliably on-premises. Nearly a quarter (21 percent) said they needed to optimize costs, while 13 percent said they needed to improve data accessibility.
- Data Protection Remains Top Priority with Other Use Cases Gaining Traction : Data protection (including disaster recovery, backup and archiving) was the most popular hybrid cloud use case selected with 29 percent stating they are either utilizing hybrid cloud for data protection today or plan to within 24 months. However, customer respondents indicated they are also leveraging hybrid cloud for production use cases more than anticipated: 20 percent said they are currently integrating both on-premises and cloud resources to support the same workload for hybrid production, with 17 percent planning to do so within 24 months.
Innovative Organizations Continue to Succeed with NetApp Hybrid Cloud Solutions
The survey data shows that organizations all over the world are adopting a hybrid cloud strategy and relying on NetApp’s industry-leading solutions to accelerate their digital transformation and deliver business value faster.
“We needed the flexibility and agility of a hybrid cloud architecture to more effectively manage the massive amounts of data being generated daily across our global manufacturing facilities and development sites to accelerate time to insights and better inform decision making,” said Rohit Agrawal, Global Head of Hybrid Cloud at Siemens Healthineers. “NetApp’s hybrid cloud solutions help us streamline data center operations and keep costs under control, with the ability to centralize, manage, and secure the mission-critical data and applications.”
Methodology
The survey was conducted by NetApp among 79 organizations (54% AMER, 36% EMEA, 10% APAC) representing large and midsized organizations across diverse industries that have deployed or plan to deploy hybrid cloud architectures with NetApp.
Additional Resources
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom